19-<(1,1-dimethylethoxy)carbonyl>-9,13-dioxo-14-oxa-2,10,12,19,23-pentaaza-tetracosanedioic acid, 1-(phenylmethyl) 24-(1,1-dimethylethyl) ester | 185248-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 19-<(1,1-dimethylethoxy)carbonyl>-9,13-dioxo-14-oxa-2,10,12,19,23-pentaaza-tetracosanedioic acid, 1-(phenylmethyl) 24-(1,1-dimethylethyl) ester
• 英文别名: 19-[(1,1-Dimethylethoxy)carbonyl]-9,13-dioxo-14-oxa-2,10,12,19,23-pentaazatetracosanedioic acid, 1-(phenyl-methyl) 24-(1,1-dimethylethyl) ester；tert-butyl N-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]-N-[4-[[7-(phenylmethoxycarbonylamino)heptanoylamino]methylcarbamoyloxy]butyl]carbamate
• CAS: 185248-00-4
• 化学式: C₃₄H₅₇N₅O₉
• 分子量: 679.855
• InChiKey: OVHHRVILCHNPMQ-UHFFFAOYSA-N

物化性质

• 沸点：
  830.3±65.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  48.0
• 可旋转键数：
  20.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  173.63
• 氢给体数：
  4.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  19-<(1,1-dimethylethoxy)carbonyl>-9,13-dioxo-14-oxa-2,10,12,19,23-pentaaza-tetracosanedioic acid, 1-(phenylmethyl) 24-(1,1-dimethylethyl) ester 在 palladium on activated charcoal 氢气 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 125.0h， 生成 7-<(aminoiminomethyl)amino>-N-<<4-<(3-aminopropyl)amino>butoxy>carbonylaminomethyl>heptanamide, tris(trifluoroacetate)
  参考文献：
  名称：

  Structure−Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 1. Structural Modifications of the Hydroxyglycine Moiety

  摘要：

  A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent currently commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Using the general concept of bioisosteric replacement, variations of the hydroxyglycine central "C" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. By this way, the malonic derivative 13a was discovered as the first example of a new series of potent immunosuppressive agents encompassing a retro-amide bond linked to the hexyl-guanidino moiety. Structure-activity relationships of this series were studied by synthesizing compounds 13g-i and 13k-s. Variation of the "right-amide" of 13a led to the urea 19a and the carbamates 23 and 27a which proved to be equally active as DSG in our GVHD model. Finally 27a was found to be the most potent derivative, being slightly more active than DSG in a heart allotransplantation model in rats. Due to the absence of chiral center in its structure and to its improved chemical stability compared to DSG, 27a was selected as a candidate for clinical evaluation.

  DOI：

  10.1021/jm980431g
• 作为产物：
  描述：

  N-(6-cyanohexanoyl)glycine 在 镍 sodium hydroxide 、 二苯基膦叠氮化物 、 氢气 、 sodium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 、 甲苯 为溶剂， 25.0 ℃ 、350.0 kPa 条件下， 反应 32.75h， 生成 19-<(1,1-dimethylethoxy)carbonyl>-9,13-dioxo-14-oxa-2,10,12,19,23-pentaaza-tetracosanedioic acid, 1-(phenylmethyl) 24-(1,1-dimethylethyl) ester
  参考文献：
  名称：

  Structure−Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 1. Structural Modifications of the Hydroxyglycine Moiety

  摘要：

  A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent currently commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Using the general concept of bioisosteric replacement, variations of the hydroxyglycine central "C" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. By this way, the malonic derivative 13a was discovered as the first example of a new series of potent immunosuppressive agents encompassing a retro-amide bond linked to the hexyl-guanidino moiety. Structure-activity relationships of this series were studied by synthesizing compounds 13g-i and 13k-s. Variation of the "right-amide" of 13a led to the urea 19a and the carbamates 23 and 27a which proved to be equally active as DSG in our GVHD model. Finally 27a was found to be the most potent derivative, being slightly more active than DSG in a heart allotransplantation model in rats. Due to the absence of chiral center in its structure and to its improved chemical stability compared to DSG, 27a was selected as a candidate for clinical evaluation.

  DOI：

  10.1021/jm980431g